Vaxart, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$104M
↑+586.5% +$89Mvs FY2024 (Q4)
Gross Profit
$104M
↑+586.5% +$89Mvs FY2024 (Q4)
Operating Income
$26M
Net Income
$24M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $104M | $15M |
| COGS | $0 | $0 |
| Gross Profit | $104M | $15M |
| R&D | $45M | $23M |
| SG&A | $0 | $0 |
| D&A | $2M | $2M |
| Other OpEx | $31M | $0 |
| Operating Income | $26M | $0 |
| Interest Exp. | $547K | $0 |
| Other Non-Op | $411K | $0 |
| Pretax Income | $25M | $0 |
| Tax | $459K | $0 |
| Net Income | $24M | $0 |
QuarterCharts · SEC EDGAR data · VXRT · Comparing FY2025 (Q4) vs FY2024 (Q4)